SaNOtize ^Company

SaNOtize, co-founded by Israeli-Canadian scientist Dr. Gilly Regev, was granted approval by Health Canada to conduct a Phase II prevention and efficacy trial for its proposed antiviral early treatment for use against COVID-19. SaNOtize has developed and patented (issued) a Nitric Oxide Releasing Solution platform technology to treat and prevent microbial infections, including drug resistant microbes. Target indications include treatment for strep throat, athlete's foot, infected wounds, diabetic foot ulcers, sinusitis, cold and flu and others. With antibiotic resistance increasing in the world, SaNOtize's platform technology can help fight resistance and bring a new innovating solution to fight infections.